Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada
The optimal strategy for preventing respiratory syncytial virus disease in Canadian infants depends on product price and regional risk level and resource use. Canadian policy should account for these factors.
Authors
- Shweta Mital (ORCID: https://orcid.org/0009-0008-2440-4313)
- Shawn Bugden (ORCID: https://orcid.org/0000-0002-9842-5909)
- Hai V. Nguyen (ORCID: https://orcid.org/0000-0002-2578-170X)
Institutions
- Memorial University of Newfoundland (CA)
- Université Bourgogne Franche-Comté (FR)
- University of Manitoba (CA)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1186/s12916-025-03928-z
- Citations
- 8
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 10.83